Print Preview Area

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Clinical Cancer Research, 06/29/2012

Vitale LA et al. – The data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX–1127, may provide direct antitumor activity against CD27–expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia Clinical Cancer Research, 06/29/2012

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
Clinical Cancer Research, 06/29/2012